Search

Displaying results 2351 - 2360 of 10000 in total
  1. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. … [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency,

  2. Drug

    Terbutaline

    go.drugbank.com/drugs/DB00871
    ApprovedInvestigational

    Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s and early 1970s. … [A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088]

    Products: บรองโคนิล (N)
  3. Drug

    Desvenlafaxine

    go.drugbank.com/drugs/DB06700
    ApprovedInvestigational

    [L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … [A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).

  4. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [L51973] When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated

  5. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_. … Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin.

  6. Drug

    Ensifentrine

    go.drugbank.com/drugs/DB16157
    ApprovedInvestigational

    [L50903] It works to induce bronchodilator and reduce inflammation in COPD.[A263913] … Ensifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes.

    Synonyms: N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREA, UREA, N-(2-(6,7-DIHYDRO-9,10-DIMETHOXY-4-OXO-2-((2,4,6-TRIMETHYLPHENYL)IMINO)-2H-PYRIMIDO(6,1-A)ISOQUINOLIN-3(4H)-YL)ETHYL)-
  7. Drug

    Garetosmab

    go.drugbank.com/drugs/DB16379
    ApprovedInvestigational

    [L63940,L64047] It is the second therapy approved for FOP, following [palovarotene] (Sohonos), which was approved in 2023, and is the first FOP therapy shown to reduce clinician-assessed flare-ups. … [L63940] It is a fully human IgG4 monoclonal antibody that binds and neutralizes activin A, blocking activin A from activating the mutant ACVR1 receptor that, in FOP, drives the formation of heterotopic

  8. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome. … Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

  9. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy … Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.

    Synonyms: 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide
  10. Drug

    Fenofibric acid

    go.drugbank.com/drugs/DB13873
    ApprovedInvestigational

    Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. … It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.